CD63 and breast adenocarcinoma: The study began by determination of the differences in the abundance of CD63 and HER2 in the EVs prepared from colorectal cancer cells (HT‐29), breast adenocarcinoma cells (SKRB3) and hepatocellular carcinoma cells (HepG2) (Figure S6).